Browse 26 Market Data Tables and 28 Figures spread through 187 Pages and in-depth TOC on "Nonalcoholic Steatohepatitis
Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
Mantzoros, "Adiponectin as a target for the treatment of nonalcoholic steatohepatitis
with thiazolidinediones: a systematic review," Metabolism, vol.
Hritz et al., "Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis
and fibrosis in mice," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis
(FLINT): a multicentre, randomised, placebo-controlled trial.
Natural history of nonalcoholic steatohepatitis
: A longitudinal study of repeat liver biopsies.
: histologic features and clinical correlations with 30 blinded biopsy specimens.
The liver disease in these patients can fall anywhere in the spectrum from simple NAFLD all the way to nonalcoholic steatohepatitis
(NASH), in which histologic findings range from fat plus ballooning degeneration to fat plus alcoholic hepatitis-like lesions that are impossible to distinguish from those of alcoholic liver disease.
(NASDAQ: GILD) and US-based healthcare network the Renown Institute for Health Innovation have forged a strategic collaboration to collect and analyse genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis
and potentially inform development of treatment options for the disease, the principals said.
Gilead and the Renown Institute for Health Innovation, or IHI, announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis
, or NASH and potentially inform development of treatment options for the disease.
The contract has been signed for Yuhan's fusion protein for the treatment of Nonalcoholic Steatohepatitis
(NASH) and related liver diseases.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis
(NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.